Equities research analysts at StockNews.com started coverage on shares of Akari Therapeutics (NASDAQ:AKTX – Get Free Report) in a research note issued on Saturday. The brokerage set a “sell” rating on the biopharmaceutical company’s stock.
Akari Therapeutics Trading Up 15.8 %
AKTX stock opened at $2.78 on Friday. Akari Therapeutics has a 1-year low of $1.08 and a 1-year high of $4.40. The business’s 50 day moving average is $3.01 and its 200-day moving average is $2.77.
Akari Therapeutics Company Profile
Read More
- Five stocks we like better than Akari Therapeutics
- What Are Dividend Contenders? Investing in Dividend Contenders
- Energy Vault Soars 100%: CEO Shares Why in MarketBeat Exclusive
- Russell 2000 Index, How Investors Use it For Profitable Trading
- Meta’s Q3 Earnings Beat—Is This Dip a Golden Entry Opportunity?
- Why Invest in High-Yield Dividend Stocks?
- Top Nuclear Stocks Thriving on Soaring Energy Demand
Receive News & Ratings for Akari Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akari Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.